GNPX Genprex Inc
Price (delayed)
$0.295
Market cap
$7.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.34
Enterprise value
$5.52M
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new
Highlights
The company's EPS has surged by 76% YoY and by 54% QoQ
The net income has grown by 32% year-on-year and by 7% since the previous quarter
Genprex's equity has plunged by 78% YoY and by 2.7% from the previous quarter
GNPX's quick ratio has dropped by 69% year-on-year and by 3% since the previous quarter
Key stats
What are the main financial stats of GNPX
Market
Valuations
Earnings
Shares outstanding
24.15M
Market cap
$7.13M
Enterprise value
$5.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$21.17M
Net income
-$21.11M
EBIT
-$21.11M
EBITDA
-$21.1M
Free cash flow
-$17.15M
Per share
Balance sheet
Liquidity
EPS
-$5.34
EPS diluted
-$5.34
Free cash flow per share
-$4.28
Book value per share
$0.19
Revenue per share
$0
TBVPS
$1.03
Total assets
$4.12M
Total liabilities
$2.5M
Debt
$0
Equity
$1.62M
Working capital
-$426,703
Debt to equity
0
Current ratio
0.83
Quick ratio
0.64
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-314.5%
Return on equity
-522.1%
Return on invested capital
-4,612.4%
Return on capital employed
-1,303%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GNPX stock price
How has the Genprex stock price performed over time
Intraday
28.21%
1 week
-22.37%
1 month
-21.75%
1 year
-89.61%
YTD
-65.36%
QTD
20.26%
Financial performance
How have Genprex's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.17M
Net income
-$21.11M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 32% YoY and by 7% QoQ
The net income has grown by 32% year-on-year and by 7% since the previous quarter
Growth
What is Genprex's growth rate over time
Valuation
What is Genprex stock price valuation
P/E
N/A
P/B
1.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 76% YoY and by 54% QoQ
Genprex's equity has plunged by 78% YoY and by 2.7% from the previous quarter
The P/B is 57% below the 5-year quarterly average of 2.8 and 24% below the last 4 quarters average of 1.6
Efficiency
How efficient is Genprex business performance
The ROE has shrunk by 113% YoY and by 27% QoQ
The company's return on invested capital has surged by 71% YoY and by 13% QoQ
GNPX's ROA has plunged by 70% YoY and by 17% from the previous quarter
Dividends
What is GNPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GNPX.
Financial health
How did Genprex financials performed over time
Genprex's total assets is 65% higher than its total liabilities
GNPX's quick ratio has dropped by 69% year-on-year and by 3% since the previous quarter
GNPX's current ratio has dropped by 64% year-on-year and by 3.5% since the previous quarter
Genprex's debt is 100% lower than its equity
Genprex's equity has plunged by 78% YoY and by 2.7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.